“Dual neutralization of IL-17A and IL-17F with bimekizumab improves quality of life in patients withmoderate-to-severe plaque psoriasis: results from a Phase 2b study and correlation with clinical response”, J of Skin, vol. 2, p. S92, Dec. 2018, doi: 10.25251/skin.2.supp.93.